Home Blog of Signal Transduction GPCR & G Protein Vasopressin Receptor Hyponatremia Associated with Congestive Heart Failure: Involvement of Vasopressin and Efficacy of Vasopressin Receptor Antagonists

Category

Archives

Popular Post

ESKM, a novel therapeutic agent for sensitive and resistant PH+ leukemias

The mechanism of resistance to JAK2 inhibitor in myeloproliferative neoplasms patients

Effects of PARP inhibitors in BRCA gene-mutated ovarian cancer

DASATINIB; An inhibitor of Receptor Tyrosine Kinase

GP130/JAK/STAT3 signaling pathway induces multiple myeloma

Hyponatremia Associated with Congestive Heart Failure: Involvement of Vasopressin and Efficacy of Vasopressin Receptor Antagonists

Hyponatremia is frequently found in patients with congestive heart failure. A reduction in effective circulatory blood volume in a volume-expanded patient with decreased cardiac output is linked to a baroreceptor-mediated non-osmotic release of arginine vasopressin (AVP). The increased production of AVP and salt and water retention in the proximal and distal tubules of the kidney by humoral, hemodynamic, and neural mechanisms increase circulatory blood volume and contribute to hyponatremia. Recent studies have indicated that hyponatremia predicts the short-term and long-term prognosis of heart failure by increasing cardiac death and rehospitalization. In addition, the early development of hyponatremia in acute myocardial infarction also predicts the long-term prognosis of worsening heart failure. AVP V2 receptor antagonism may relieve water retention, but it is unknown whether the V2 receptor inhibitor, tolvaptan, improves the long-term prognosis of congestive heart failure. The newly identified natriuretic factor in renal salt wasting has the potential of improving clinical outcomes when combined with a distal diuretic.

 

Comments：

Hyponatremia is a common finding in patients with congestive heart failure due to the activation of the renin-angiotensin-aldosterone system and the release of arginine vasopressin (AVP). AVP promotes water reabsorption in the kidneys, which can lead to dilutional hyponatremia. Studies have shown that hyponatremia is a predictor of poor outcomes in heart failure patients, including increased risk of cardiac death and rehospitalization.

One potential treatment for hyponatremia in heart failure patients is the use of AVP V2 receptor antagonists, such as tolvaptan, which can increase free water excretion and improve serum sodium levels. However, it is currently unclear whether the use of these agents can improve long-term outcomes in heart failure patients.

Another potential treatment option for hyponatremia in heart failure is the use of natriuretic factors, which promote natriuresis and diuresis. Recent studies have identified a new natriuretic factor involved in renal salt wasting, which could potentially be used in combination with distal diuretics to improve clinical outcomes in heart failure patients.

Overall, the presence of hyponatremia in heart failure patients is a predictor of poor outcomes, and further research is needed to determine the most effective treatment strategies for this condition.

Related Products

Cat.No. Product Name Information
S2593 Tolvaptan Tolvaptan (OPC-41061) is an orally effective nonpeptide arginine vasopressin V2 receptor antagonist with IC50 of 3 nM, used to treat hyponatremia.

Related Targets

Vasopressin Receptor